
Stem Cells Incorporation has received approval from the U.S. Food and Drug Administration (FDA of USA) to begin a Phase ½ clinical trial of the company’s human embryonic stem cells, a product for the treatment of dry age-related macular degeneration, according to the company’s announcement.
Read More